Large Cap Biotech
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Trend Stats
1-Month Return
+5.08%
3-Month Return
+15.73%
12-Month Return
+43.24%
Volatility Score
1.8
RSI
63.1
ST Trend
Up
LT Trend
Up
Short-Term Trend
Up
The Short-Term Trend is a metric that gauges an ETF's short-term price trend.
Long-Term Trend
Up
The Long-Term Trend is a metric that gauges an ETF's long-term price trend.
Performance
Large Cap Biotech
S&P 500 Index
Components
| Symbol | Company | Market Cap | 12 mo return Performance over the past 12 months | 3 mo return Performance over the past 3 months | 1 mo return Performance over the past month | Vol Score Our gauge of the ETF's recent volatility | ST Trend A metric that gauges an ETF's short-term price trend | LT Trend A metric that gauges an ETF's long-term price trend |
|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen | $225B | +44.26% | +24.42% | +16.88% | 2.8 | Up | Up |
| GILD | Gilead Sciences | $172B | +19.93% | +5.46% | +6.40% | 2.8 | Up | Up |
| VRTX | Vertex Pharma | $128B | +28.76% | +12.29% | +6.18% | 2.9 | Up | Up |
| REGN | Regeneron Pharma | $83B | +39.19% | +12.88% | +22.46% | 2.6 | Up | Up |
| ARGX | arGEN-X SpADR | $53B | +30.20% | +3.55% | -0.95% | 3.2 | Down | Neutral |
| NTRA | Natera | $45B | +90.12% | +57.40% | +13.67% | 4.2 | Up | Up |
| RVMD | REVOLUTION MEDIC | $44B | +460.88% | +36.29% | +10.13% | 3.7 | Up | Up |
| ONC | BeOne Medi Sp ADR | $39B | +8.13% | +14.07% | +13.35% | 2.8 | Up | Up |
| BIIB | Biogen | $31B | +51.39% | +9.65% | +9.31% | 3.1 | Up | Up |
| ALNY | Alnylam Pharma | $31B | -49.07% | -22.08% | -18.71% | 6.0 | Down | Down |
| ILMN | Illumina | $29B | +90.68% | +33.27% | -0.16% | 4.1 | Up | Up |
| INSM | Insmed | $27B | -3.18% | +7.02% | +12.38% | 4.6 | Up | Down |
| ROIV | ROIVANT SCIENCES | $26B | +205.49% | +22.71% | +3.70% | 3.4 | Up | Up |
| MRNA | MODERNA | $25B | +125.98% | +26.56% | -6.11% | 5.3 | Up | Up |
| INCY | Incyte | $24B | +38.24% | +23.08% | +4.60% | 3.3 | Up | Up |
| BNTX | BioNTech Sp ADR | $23B | -18.00% | +1.20% | +2.98% | 2.7 | Neutral | Down |
| UTHR | United Therapeut | $21B | +59.59% | -13.21% | -5.11% | 2.8 | Down | Down |
| GMAB | GENMAB SP ADR | $20B | +37.02% | +18.74% | +11.17% | 2.5 | Up | Up |
| ASND | Ascendis Pharma Br | $16B | +25.30% | +1.23% | -6.43% | 3.1 | Neutral | Up |
| MEDP | Medpace Holdings | $16B | +26.35% | +38.01% | +7.89% | 4.0 | Up | Up |
| BBIO | BRIDGEBIO PHARMA | $16B | +55.61% | +14.64% | -5.03% | 3.5 | Up | Up |
| NBIX | Neurocrine Biosc | $16B | +14.91% | -3.98% | -11.23% | 4.0 | Down | Up |
| CRL | Charles Riv Lab | $13B | +78.74% | +76.00% | +21.12% | 3.7 | Up | Up |
| BMRN | Biomarin Pharm | $13B | +17.07% | +26.52% | +14.87% | 2.9 | Up | Up |
| EXEL | Exelixis | $13B | +33.75% | +0.27% | -8.12% | 3.5 | Down | Up |
| ARWR | Arrowhead Phrmct | $12B | +322.43% | +8.72% | +20.48% | 4.8 | Up | Up |
| MDGL | Madrigal Pharmct | $12B | +37.24% | -5.99% | -5.46% | 4.8 | Down | Down |
| TECH | Bio-Techne | $11B | +35.89% | +62.12% | +1.64% | 0.5 | Up | Up |
| HALO | Halozyme Therape | $11B | +46.66% | +42.55% | +31.46% | 3.2 | Up | Up |
| AXSM | Axsome Therapeut | $11B | +95.64% | -8.01% | -9.18% | 4.3 | Down | Up |
| SMMT | SUMMIT THERAP | $11B | -49.98% | -26.41% | -13.70% | 6.6 | Down | Down |
| ABVX | ABIVAX SP ADS | $10B | +68.88% | -1.69% | -11.82% | 4.3 | Down | Neutral |
| CYTK | Cytokinetics | $10B | +91.70% | -5.73% | -9.52% | 3.9 | Down | Up |
| PRAX | PRAXIS PRECIS | $10B | +679.12% | +6.16% | +11.94% | 5.3 | Up | Up |
| APGE | APOGEE THERAP | $10B | +260.82% | +60.35% | +0.44% | 0.2 | Up | Up |
| PTGX | Protagonist Ther | $10B | +176.62% | +46.94% | +18.15% | 3.8 | Up | Up |
| KRYS | KRYSTAL BIOTECH | $9.8B | +121.12% | +5.05% | -2.11% | 4.6 | Down | Up |
| KYMR | KYMERA THERAP | $9.8B | +175.37% | +38.92% | +4.74% | 3.9 | Up | Up |
| IONS | Ionis Pharmaceut | $9.5B | +30.74% | -24.37% | +4.21% | 3.5 | Down | Down |
| RGEN | Repligen | $9.4B | +34.17% | +61.38% | +13.39% | 4.8 | Up | Up |
| 0 | 0 | 0 | 0 | Bullish | Bullish |